The study directly compares Zepbound and Wegovy for weight loss results

Do weight loss drugs continue to grow popular as an anti-obesity tool, but are some more effective than others?

The question was explored in a new study published this month in the New England Journal of Medicine.

The researchers compared the safety and effectiveness of the Tirzepatida (Zepbound brand name) and Semaglutide (WEGOVY brand name) in a 72 -week clinical trial.

Weight loss drugs may also benefit the common medical problem, according to study

The random and controlled essay, called Surmount-5, included 751 people in all the United States and Puerto Rico who had obesity, but not type 2 diabetes.

“Doctors, insurance companies and patients always ask:” Which drug is most effective? “, Said Dr. Louis Aronne, director of the Weight Comprehensive Control Center, and Sanford I. Weill’s Metabolic Research Professor in Weill Cornell Medicine.” This study allowed us to make a direct comparison. ”

“The results are consistent with, in fact, almost identical to those, with what we have seen in the trials in which these medicines were evaluated independently,” added Aronne, who was a lead researcher at the trial.

The study found that the Tirzepatida gained greater weight loss, and participants spilled about 50 pounds (20.2% of their body weight).

“Doctors, insurance companies and patients always ask:” Which drug is most effective? “”

The group that takes the semaglutide lost an average of 33 pounds or 13.7% of its initial weight, according to a press statement that summarizes the result of the study.

Generally, 32% of people who took Tirzepatida lost at least 25% of their body weight; Semaglutid users lost about 16%.

Weight loss, diabetes drugs can cause mood changes: what to know about the side effects of behavior

Tirzepatide users also reported a “greater reduction in the circumference of the waist” than those of the semaglutide.

The probable reason for Tirzepatide’s greater effectiveness is that he uses a “double action mechanism”, according to Aronne.

“While the semaglutide works by activating the receptors for a hormone called peptide 1 similar to glucagon, or GLP-1, imitates the pyrzepatid not only GLP-1, but also an additional hormone, glucose dependent insulototropic peptide (GIP), said the launch.

“As a whole, these actions reduce hunger, lower levels of blood glucose and affect the metabolism of fat cells.”

The impact of medicines for weight loss on the risk of cancer revealed in a new study

Additional trials actively explore if the Tyrzepatid also reduces the risk of heart attack and stroke, a benefit that has been linked to the semaglutide.

The study was led by a Weill Cornell Medicine and Newyork-Presbyterian researcher. It was also carried out with the University of Texas McGoVern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin and Eli Lilly (Zepbound maker).

All participants received nutrition and exercise guidance.

The side effects reported were very similar to the two drugs, with 44% of people who experience nausea and 25% with abdominal pain.

Medicines for weight loss to obtain amazing support from the Global Health Giant

Dr. Ada Londono, MD, an obesity certified by the Board and a primary care physician in Internal Medicine with Plushcare, a virtual health platform that offers Primary Care Services, Therapy and Weight Management, said that the study’s conclusions was not surprised.

“The results are consistent with the previous trials, confirming Tirzepatide’s advantage over the unique Semaglutide GLP-1 action,” said Londono, based in New York City, in Fox News Digital.

Beyond weight loss, semaglutide has also shown potential benefits to cardiovascular health, sleep apnea and kidney disease, he said.

“These findings highlight the need for continuous research to understand the broader impacts of Tirzepatide’s health,” he said. “It is encouraging to see studies in progress exploring all the potential of GLP-1 medicines beyond weight management.”

Londono said these treatments may have side effects.

Semaglutide had a shocking benefit for patients with liver disease in a new study

“Most people in these medicines only report mild symptoms, but some have experienced more serious reactions, such as pancreatitis,” Fox News Digital told Fox.

“This emphasizes the importance of reviewing your medical history and discussing any problems with your healthcare provider.”

Potential limitations

The study had some limitations, mainly that it was not a blind analysis and participants knew what medication they received. This could introduce some level of bias, acknowledging researchers.

Londono said that while the study’s findings are “promising”, he was funded by Eli Lilly, the Zepbound manufacturer.

“This can ask questions about possible conflicts of interest,” he said. “In addition, the design of open labels and the duration of 72 weeks can limit the objectivity and long -term vision.”

Although the study mainly studied the impact of medicines, experts agreed that there are other factors that have a role in successful weight management.

“The weight loss is biological, but it is also emotional, and the support of the whole person can make a difference between short -term results and sustainable health,” said Dr. Rekha Kumar, a medical manager for the weight care program and a practicing endocrinologist in New York City, told Fox News Digital.

Click here to get the Fox News app

Kumar emphasized the importance of working with a doctor to choose a medicine to lose weight that coincides with the personal goals and health status of the patient.

“Both Wegovy and Zepbound have shown a clinically significant weight reduction in weight.”

“For example, if a patient has fat liver, we will choose the GLP-1 that is shown to work best for liver disease,” he said.

In front, researchers are planning to investigate new drug versions for losing weight, including the portrutide, which mimics GLP-1, GIP and glucagon hormones, according to the statement.

Click here to register -you are in our health newsletter

“Although drugs like Tirzepatida and Semaglutide work very well, better than everything we have ever seen, we still have people who do not respond to them,” said Aronne.

“So, moving forward, we want to keep trying to do it better.”

A Novo Nordisk spokesman, the company that makes Wegovy (Semaglutide) sent a statement to Fox News Digital.

“Through the respective clinical trial programs and Surmount-5, both Wegovy and Zepbound have shown a clinically significant reduction in weight,” the company said. “It is important to recognize that the integral management of obesity goes beyond weight reduction.”

For more health items, visit www.foxnews.com/health

The spokesman also said that in a previous trial, obese or overweight adults and that they took Wegovy along with the diet and exercise lost an average of 15.2% of their weight (~ 35 pounds) in the two -year mark, compared to 2.6% (~ 6 pounds) for patients taking a placebo.